pexels anni roenkae 3625632

Recombinant Innovation Management (RIM) — How to Stimulate Breakthrough Innovation within Large R&D Organisations

Pharmaceutical R&D is in a state of crisis: productivity is declining both in terms of output per spending as well as total output, while patent expirations threaten many successful product franchises within the next years. The main issue is that impressive advances in process productivity have not translated into more novel products addressing unmet needs.

Discover Other Articles

Discover Other Articles